Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.

Reddel SW, Barnett MH, Riminton S, Dugal T, Buzzard K, Wang CT, Fitzgerald F, Beadnall HN, Erickson D, Gahan D, Wang D, Ackland T, Thompson R.

Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673. [Epub ahead of print]

PMID:
29911471
2.

Diffusivity in the core of chronic multiple sclerosis lesions.

Klistorner A, Wang C, Yiannikas C, Parratt J, Barton J, You Y, Graham SL, Barnett MH.

PLoS One. 2018 Apr 25;13(4):e0194142. doi: 10.1371/journal.pone.0194142. eCollection 2018.

3.

We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Yes.

Garber JY, Barnett MH.

Mult Scler. 2018 Apr 1:1352458518770970. doi: 10.1177/1352458518770970. [Epub ahead of print] No abstract available.

PMID:
29656673
4.

The evolution of "No Evidence of Disease Activity" in multiple sclerosis.

Lu G, Beadnall HN, Barton J, Hardy TA, Wang C, Barnett MH.

Mult Scler Relat Disord. 2018 Feb;20:231-238. doi: 10.1016/j.msard.2017.12.016. Epub 2017 Dec 25. Review.

PMID:
29579629
5.

Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study.

Klistorner A, Wang C, Yiannikas C, Parratt J, Dwyer M, Barton J, Graham SL, You Y, Liu S, Barnett MH.

Neuroimage Clin. 2017 Dec 8;17:1028-1035. doi: 10.1016/j.nicl.2017.12.010. eCollection 2018.

6.

White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.

Wang C, Klistorner A, Ly L, Barnett MH.

PLoS One. 2018 Jan 17;13(1):e0191131. doi: 10.1371/journal.pone.0191131. eCollection 2018.

7.

Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS.

You Y, Graham EC, Shen T, Yiannikas C, Parratt J, Gupta V, Barton J, Dwyer M, Barnett MH, Fraser CL, Graham SL, Klistorner A.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e427. doi: 10.1212/NXI.0000000000000427. eCollection 2018 Jan. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jan 31;5(2):e444.

8.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15.

9.

Exosomal microRNA signatures in multiple sclerosis reflect disease status.

Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, Beadnall H, Barnett MH, Suter CM, Buckland ME.

Sci Rep. 2017 Oct 30;7(1):14293. doi: 10.1038/s41598-017-14301-3.

10.

Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions.

Aw ST, Chen L, Todd MJ, Barnett MH, Halmagyi GM.

J Neurol. 2017 Oct;264(10):2119-2129. doi: 10.1007/s00415-017-8607-8. Epub 2017 Sep 6.

PMID:
28879396
11.

Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.

Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N, Yiannikas C, Lin CS, Spies JM, Ghaoui R, Barnett MH, Vucic S, Pollard JD, Kiernan MC.

J Neuroimmunol. 2017 Aug 15;309:41-46. doi: 10.1016/j.jneuroim.2017.05.002. Epub 2017 May 13.

PMID:
28601286
12.

Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes.

Dale RC, Barnett MH, Kiernan MC.

J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):713-714. doi: 10.1136/jnnp-2017-315724. Epub 2017 Jun 8. No abstract available.

PMID:
28596249
13.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
14.

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

De Stefano N, Silva DG, Barnett MH.

CNS Drugs. 2017 Apr;31(4):289-305. doi: 10.1007/s40263-017-0415-2. Review.

15.

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH.

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8. No abstract available.

PMID:
28179462
16.

Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework.

Jain S, Ribbens A, Sima DM, Cambron M, De Keyser J, Wang C, Barnett MH, Van Huffel S, Maes F, Smeets D.

Front Neurosci. 2016 Dec 19;10:576. doi: 10.3389/fnins.2016.00576. eCollection 2016.

17.

Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.

Beadnall HN, Gill AJ, Riminton S, Barnett MH.

Neurology. 2016 Dec 13;87(24):2595-2597. Epub 2016 Nov 16. No abstract available.

PMID:
27856777
18.

Neurological deficit following stereotactic radiosurgery for trigeminal neuralgia.

Kemp S, Allan RS, Patanjali N, Barnett MH, Jonker BP.

J Clin Neurosci. 2016 Dec;34:229-231. doi: 10.1016/j.jocn.2016.09.029. Epub 2016 Oct 17.

PMID:
27760694
19.

Diffusivity in multiple sclerosis lesions: At the cutting edge?

Klistorner A, Wang C, Fofanova V, Barnett MH, Yiannikas C, Parratt J, You Y, Graham SL.

Neuroimage Clin. 2016 Jul 5;12:219-26. doi: 10.1016/j.nicl.2016.07.003. eCollection 2016.

20.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954

Supplemental Content

Loading ...
Support Center